Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab Post-Trial Access Study in Multiple Myeloma
2023-505200-33-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Nov 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of elranatamab in multiple myeloma (MM), sponsored by Pfizer. Primary endpoints: Nonserious adverse events leading to permanent discontinuation of elranatamab and All serious adverse events (SAEs). Planned start Nov 2023; status: authorised.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-505200-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505200-33-00.